Bioavailability of Δ9-tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spray delivery system in conscious rabbits

Drug Development and Industrial Pharmacy

Volumn 37, Issue 3, 2011, Pages 329-334

  Al Ghananeem, Abeer M ^a   Malkawi, Ahmad H ^a   Crooks, Peter A ^a  

^a University of Kentucky   (United States)

Author keywords

9 tetrahydrocannabenol; Chitosan; gel; LC MS; nasal; Pharmacokinetic

Indexed keywords

CHITOSAN; DRONABINOL; EXCIPIENT; PSYCHOTROPIC AGENT; TETRAHYDROCANNABINOL;

AEROSOL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG STRUCTURE; GEL; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RABBIT; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOAVAILABILITY; BLOOD; CHEMISTRY; INTRANASAL DRUG ADMINISTRATION; METABOLISM; MUCOCILIARY CLEARANCE; MUCOSAL ADMINISTRATION; NOSE MUCOSA;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, MUCOSAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHITOSAN; EXCIPIENTS; GELS; MALE; MUCOCILIARY CLEARANCE; NASAL MUCOSA; PSYCHOTROPIC DRUGS; RABBITS; TETRAHYDROCANNABINOL;

EID: 79952935220     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.513009     Document Type: Article

References (23)

1. Watson SJ, Benson Jr. JA, Joy JE. (2000). Marijuana and medicine: Assessing the science base. Arch Gen Psychiatry, 57:547-52.
2. Wilson DM, Peart J, Martin BR, Bridgen DT, Byron PR, Lichtman AH. (2002). Physiochemical and pharmacological characteriza-tion of a Delta(9)-THC aerosol generated by a metered dose inhaler. Drug Alcohol Depend, 67:259-67. (Pubitemid 34786261)
3. Jarvinen T, Pate DW, Laine K. (2002). Cannabinoids in the treat-ment of glaucoma. Pharmacol Ther, 95:203-20.
4. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. (1991). Recent clinical experience with dronab-inol. Pharmacol Biochem Behav, 40:695-700.
5. Voth EA, Schwartz RH. (1997). Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med, 126:791-8. (Pubitemid 27209646)
6. Berman JS, Symonds C, Birch R. (2004). Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Results of a randomized con-trolled trial. Pain, 112:299-306. (Pubitemid 39550730)
7. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J. (2005). Cannabinoids provide neuroprotec-tion against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease. Neurobiol Dis, 19:96-107. (Pubitemid 40544727)
8. Hall W, Christie M, Currow D. (2005). Cannbinoids and cancer: Causation, remediation, and palliation. Lancet Oncol, 6:35-42.
9. Bland TM, Haining RL, Tracy TS, Callery PS. (2005). CYP2C-catalyzed delta9-tetrahydro-cannabinol metabolism: Kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol, 70:1096-103. (Pubitemid 41262085)
10. Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y. (1996). The effect of orally and rectally administered delta 9-tetrahydro-cannabinol on spasticity: A pilot study with 2 patients. Int J Pharmacol Ther, 34:446-52. (Pubitemid 26341135)
11. Al-Ghananeem AM, Traboulsi AA, Dittert LW, Hussain AA. (2002). Targeted brain delivery of 17-beta-estradiol via nasally administered water soluble prodrugs. AAPS PharmSciTech, 3:5.
12. Hussain AA. (1998). Intranasal drug delivery. Adv Drug Deliv Rev, 29:39-49. (Pubitemid 28044085)
13. Romeo VD, deMeireles J, Sileno AP, Pimplaskar HK, Behl CR. (1998). Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Deliv Rev, 29:89-116. (Pubitemid 28044088)
14. Bechgaard E, Gizurarson S, Hjortkjaer RK. (1997). Pharmacoki-netic and pharmacodynamic response after intranasal adminis-tration of diazepam to rabbits. J Pharm Pharmacol, 49:747-50. (Pubitemid 27386893)
15. Li L, Gorukanti S, Choi YM, Kim KH. (2000). Rapid-onset intranasal delivery of anticonvulsants: Pharmacokinetic and pharmacodynamic evaluation in rabbits. Int J Pharm, 199:65-76. (Pubitemid 30224506)
16. Peeters J, Neeskens P, Brewster ME. (2007). Development of a formulation of pirodavir using 2-hydroxypropyl-β-cyclodextrin. J Inc Phen Macrocycl Chem, 57:137-9.
17. Hussain AA, Dittert LW, Qaisi AM, Traboulsi A. (2000). Method for enhancement of delivery of THC by the administration of its prodrugs via the nasal route. PCT Int Appl, 27:1-27.
18. Valiveti S, Agu RU, Hammell DC, Paudel KS, Earles DC, Wermeling DP, et al. (2007). Intranasal absorption of Δ9-tetrahydrocannab-inol and WIN55, 212-2 mesylate in rats. Eur J Pharm Biopharm, 65:247-52. (Pubitemid 46038085)
19. Patel JK, Patel RP, Amin AF, Patel MM. (2005). Formulation and evaluation of mucoadhesive glipizide microspheres. AAPS PharmSciTech, 6:49-55.
20. Chien YW, Chang SF. (1987). Intranasal drug delivery for systemic medication. Crit Rev Ther Drug Carrier Syst, 4:67-194. (Pubitemid 18042038)
21. Barichello JM, Morishita M, Takayama K, Nagai T. (1999). Absorption of insulin from pluronic F-127 gels following subcu-taneous administration in rats. Int J Pharm, 184:89-98.
22. Pelser A, Muller DG, du Plessis J, du Preez JL, Goosen C (2002). Comparative pharmacokinetics of single doses of doxylamine succinate following intranasal, oral and intravenous administration in rats. Biopharm Drug Dispos, 23:239-44.
23. 9-tet- rahydrocannabinol in rabbits. Life Sci, 78:1911-4.